tbuckley/cabot-search huggingface dataset:
NHS plays second fiddle to Brexit as prime minister struggles to find voice
Authors: Gareth Iacobucci
Journal: BMJ (2017)

After the buzz of the past two Conservative Party conferences, in which the party faithful were giddy from an unexpected majority (2015) and an unexpected Leave vote (2016), it was perhaps inevitable that the 2017 vintage (an unexpected loss of a parliamentary majority) lacked the same fizz, with confidence also punctured by the unexpected gains made by the Labour Party in the June general election.

The Tories are divided over Brexit, and the authority of the prime minister, Theresa May, has been badly weakened by the election result. As potential successors plot behind the scenes, this conference was supposed to be a platform for May to reassert her authority. But her speech was plagued by bad luck and descended into farce, as a prankster handed her …
A Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma
Authors: A. Diab, C. Haymaker, M. Uemura, R. Murthy, M. James, J. Geib, M. Cornfeld, S. Swann, C. Yee, J. Wargo, R. Amaria, S. Patel, H. Tawbi, I. Glitza, S. Woodman, W.-J. Hwu, M.A. Davies, W. Overwijk, C. Bernatchez, P. Hwu
Journal: Annals of Oncology (2017)
Vacunación antigripal en Europa
Authors: S Cotter, F Ryan, H Hegarty, T. J McCabe, E Keane
Journal: Eurosurveillance (2003)

Se llevo a cabo un estudio para valorar la respuesta a la vacuna antigripal en grupos de riesgo y obtener informacion sobre la practica de vacunacion en los paises europeos. Los expertos en gripe de veintiseis paises rellenaron los cuestionarios. Solo catorce de ellos proporcionaron las tasas de respuesta de personas de la tercera edad. Para los demas grupos de riesgo, facilito datos un numero incluso menor de ellos. Las vacunas suelen ser administradas por el medico general. Los incentivos economicos para medicos y pacientes podrian funcionar como estrategia destinada a aumentar las tasas de respuesta, pero debido a los escasos datos disponibles, no fue posible realizar analisis multivariables completos. Se recomendo el desarrollo de un metodo de vigilancia de la vacunacion antigripal uniforme que permita comparar los datos de las respuestas en Europa.
Death by Gun Violence—A Public Health Crisis
Authors: Howard Bauchner, Frederick P. Rivara, Robert O. Bonow, Neil M. Bressler, Mary L. (Nora) Disis, Stephan Heckers, S. Andrew Josephson, Melina R. Kibbe, Jay F. Piccirillo, Rita F. Redberg, John S. Rhee, June K. Robinson
Journal: JAMA Oncology (2017)

The shooting in Las Vegas, Nevada, that left 59 people dead, 10 times that number wounded, and thousands of people with the psychological distress from being present at the scene during and after the massacre has once again raised the issue of what we as a nation can and should do about guns.The solution lies in not just focusing on Las Vegas and the hundreds of other mass shootings that have occurred in the United States in the last 14 months, but rather to underscore that on average almost 100 people die each day in the United States from gun violence.The 36 252 deaths from firearms in the United States in 2015 1 exceeded the number of deaths from motor vehicle traffic crashes that year (36 161). 1 That same year, the US Centers for Disease Control and Prevention reported that 5 people died from terrorism.Since 1968, more individuals in the United States have died from gun violence than in battle during all the wars the country has fought since its inception. 2uns do not make individuals, their families, or homes safer and they result in far more deaths to loved ones than to an intruder intending to cause harm. 3Often forgotten is that 60.7% of the gun deaths in 2015 in the United States were suicides. 1Means used to attempt suicide matter; guns will result in suicidal deaths well over 90% of the time, whereas ingestion of pills or wrist cutting will be unsuccessful more than 90% of the time.The majority of people who try to commit suicide but survive the attempt will not go on to die from suicide 4 ; if the attempt is with a gun, there will be no second chance at life.The journals of the JAMA Network are dedicated to improving the health of people across the globe.We do so by addressing the most important public health problems harming people and publishing the best science that can be done.The journals have published important work on gun violence; in the past year this has included studies on differences in gun use during terrorist attacks in the United States compared with other countries, 5 the effect of exposure to gun violence in the media on children's interest in real guns,
Comparative and multimodal analysis of the EGFR, HER2, c-MYC, and MET copy number alteration using in situ hybridization in Korean colorectal cancer patients with integration of array-based copy number data from The Cancer Genome Atlas
Authors: Y. Kwak, S. Yun, S.K. Nam, A.N. Seo, K.S. Lee, H-K. Oh, D.W. Kim, S.B. Kang, W.H. Kim, H.S. Lee
Journal: Annals of Oncology (2017)
Infused autograft lymphocyte to monocyte ratio and survival in T-cell lymphomas post-autologous peripheral blood hematopoietic stem cell transplantation.
Authors: Luis F. Porrata, David James Inwards, Stephen Maxted Ansell, Ivana N. M. Micallef, Patrick B. Johnston, William J. Hogan, Svetomir Markovic
Journal: Journal of Clinical Oncology (2015)

e19500 Background: We recently reported that the infused autograft lymphocyte to monocyte ratio (A-LMR) is a prognostic factor for survival in B-cell lymphomas post-autologous peripheral hematopoietic stem cell transplantation (APHSCT). Thus, we set out to investigate if the A-LMR is also a prognostic factor for survival post-APHSCT in T-cell lymphomas. Methods: From 1998 to 2014, 109 T-cell lymphoma patients that underwent APHSCT were studied. Receiver operating characteristic and area under the curve identified an A-LMR ≥ 1 as the best cut-off value and validated by the k-fold cross-validation. Results: . Multivariate analysis showed A-LMR to be an independent prognostic factor for overall survival (OS) and progression-free survival (PFS). Patients with an A-LMR ≥ 1.0 experienced a superior OS and PFS versus patients with an A-LMR < 1.0 [median OS was not reached vs 17.9 months, 5-year OS rates of 87% (95 CI, 75%-94%) vs 26% (95 CI, 13%-42 %), p < 0.0001, respectively; median PFS was not reached vs 11.9 months, 5-year PFS rates of 72% (95% CI, 58%-83%) vs 16% (95% CI, 6%-32%), p < 0.0001, respectively]. Conclusions: A-LMR is also a prognostic factor for clinical outcomes in patients with T-cell lymphomas undergoing APHSCT, and provides a platform to engineer immunocompetent autograft to improve survival in T-cell lymphoma patients treated with APHSCT.
Complexity of primary care is barrier to physician associates, say GPs
Authors: Abi Rimmer
Journal: BMJ (2017)

GPs think that complexity and uncertainty in primary care are the biggest barriers to physician associates becoming part of their teams, research has found. They also considered physician associates’ inability to prescribe as a barrier to working in primary care.1

In 2014 Health Education England announced that it would create 205 physician associate posts to support primary care and emergency medicine.2 And in 2015 the health secretary, Jeremy Hunt, announced that 1000 new physician associates would be working in general practice by 2020.3

In a paper published in the British Journal of General Practice ,1 researchers from the University of Sheffield said that …
Wedge Pressure Rather Than Left Ventricular End-Diastolic Pressure Predicts Outcome in Heart Failure With Preserved Ejection Fraction
Authors: Julia Mascherbauer, Caroline Zotter-Tufaro, Franz Duca, Christina Binder, Matthias Koschutnik, Andreas A. Kammerlander, Stefan Aschauer, Diana Bonderman
Journal: JACC Heart Failure (2017)
Epidémie de listériose associée à la consommation de sandwiches vendus dans un hôpital, Royaume-Uni
Authors: S J Dawson, M R Evans, D Willby, J Bardwell, N Chamberlain, D A Lewis
Journal: Eurosurveillance (2006)

Une epidemie de listeriose a eu lieu dans la region de Swindon au Royaume-Uni au cours de l’automne 2003. Cinq cas ont ete detectes chez des femmes enceintes. Il est probable que quatre d’entre elles avaient mange des sandwiches pre-emballes provenant d’un point de vente du meme hopital. La souche de Listeria monocytogenes identifiee dans les echantillons preleves chez le fournisseur etait indiscernable de celle isolee par typage moleculaire chez les patientes. Des changements recents de la legislation sur les aliments au Royaume-Uni devraient contribuer a diminuer le risque de voir apparaitre de nouveaux cas/epidemies, comme ceux decrits ici.
GW28-e1212 Value of Electrocardiographic Left Ventricular Hypertrophy as a Predictor of Poor Blood Pressure Control: Evidence from the China Stroke Primary Prevention Trial
Authors: Zhenzhen Wang, Huihui Bao, Chunyan Zhang, Xiao Huang, Fangfang Fan, Yan Zhao, Juxiang Li, Jing Chen, Kui Hong, Yanqing Wu, Qinghua Wu, Binyan Wang, Xiping Xu, Yigang Li, Yong Huo, Xiaoshu Cheng
Journal: Journal of the American College of Cardiology (2017)
Preliminary safety and efficacy of rovalpituzumab tesirine in patients with delta-like protein 3-expressing advanced solid tumors
Authors: R. Aggarwal, A. Mansfield, H. Beltran, A.F. Farago, C.L. Hann, F. Kaye, K. Lewis, J. Niu, S. Richey, D. Smith, H.P. Soares, A. Spira, M. Taylor, S.N. Waqar, S. Lally, M. Rossi, L. Saunders, S.J. Dylla, E. Kavalerchik, L. Anthony
Journal: Annals of Oncology (2017)
Comparison of HER2 related molecular expression and its significance for clinical outcomes between the primary and paired liver metastasis in advanced gastric cancer
Authors: H. Osumi, E. Shinozaki, N. Yamamoto, K. Chin, M. Ogura, D. Takahari, T. Wakatsuki, T. Ichimura, I. Nakayama, T. Matsushima, A. Saiura, T. Yamaguchi, K. Yamaguchi
Journal: Annals of Oncology (2017)
A dose finding and PK/PD study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial
Authors: C. Kitagawa, H. Saka, T. Adachi, S. Kajikawa, K. Mori, Y. Kogure, M. Oki, K. Shimokata
Journal: Journal of Clinical Oncology (2009)

e13517 Background: Amrubicin (AMR) is a potent topoisomerase II inhibitor, and a promising agent for both small cell and non-small cell lung cancer. AMR is usually administered on days 1–3 intravenously. However, it causes severe, occasionally fatal, toxicity of leucopenia and neutropenia. The purpose of this study was to evaluate the safety and tolerability of AMR, to determine the recommended weekly dose, and to conduct a PK/PD study in patients with chemotherapy-refractory or recurrent lung cancer. Methods: Refractory or relapsed non-small cell and small cell lung cancer patients after 1 or 2 regimens, younger than 80 and with adequate main organ functions were eligible. AMR was initiated 45 mg/m2 given weekly (on day 1 and 8 q3wks). The dose level was increased by 5 mg/m2 by modified Fibonacci dose escalation scheme. Dose limiting toxicity (DLT) was assessed on the 1st cycle. Results: 16 patients were enrolled. Patients were 7 small cell lung cancer and 9 non-small cell lung cancer. 54 cycles (median: 3, range: 1–6) were administered in 5 dose levels. In 65 mg/m2 level, 3 patients had DLTs. The maximum tolerated dose was 65 mg/m2. The recommended weekly AMR dose was determined to be 60 mg/m2. Leucocytopenia, neutropenia, thrombocytopenia, and the dose level were correlated (p&lt;0.001, p=0.0012, p=0.043) respectively. Leucocytopenia, neutropenia, and amrubicinol (AMR-OH) Cmax were correlated (p=0.042, p=0.047) respectively. AUC (AUC extrapolated to concentration-zero) of AMR and AMR-OH did not depend on the dose levels. The pharmacokinetic results are shown in the Table. [Table: see text] [Table: see text]
Biomarkers before and after nephrectomy of locally advanced or metastatic renal cell carcinoma (RCC) treated with everolimus: Neorad phase 2 trial (PREDICT consortium)
Authors: S. Oudard, A. Mejean, D. Topart, R. Thuret, C. Tournigand, L. Salomon, A. Thiery-Vuillemin, G. Guichard, S. Le Moulec, A. Houlgatte, A. Guillot, N. Mottet, A. Cessot, N. Barry-Delongchamps, R. Elaidi, S. Turajlic, C. Swanton, B. Escudier, J.J. Patard, L. Albiges
Journal: Annals of Oncology (2017)
Mucolytics for COPD: negotiating a slippery slope towards proof of efficacy
Authors: Shawn D. Aaron
Journal: European Respiratory Journal (2017)

Mucolytics are medicines that modulate mucus production and decrease mucus viscosity. Their mucus thinning effects may improve mucociliary transport and thereby facilitate expectoration of mucus out of the distal bronchial tree [1]. Improved clearance and expectoration of mucus can prevent mucus plugging of small airways and may theoretically improve gas exchange and lessen the probability of post-obstructive infection. Through these complementary effects, mucolytics could potentially play a role in reducing exacerbations in chronic obstructive pulmonary disease (COPD) [2]. Clinical trials have thus far not conclusively demonstrated that mucolytics are effective therapies for COPD <http://ow.ly/wbLe30eKB7H>
Differences in survival (sv) and clinicopathologic characteristics (cpc) between right and left-sided colorectal cancer (CRC): A CARESS-CCR group study
Authors: J. Alcaide-Garcia, I. Zarcos-Pedrinaci, A. Rueda Domínguez, F. Rivas-Ruiz, T. Tellez, M.M. Morales Suarez-Varela, E. Briones, M. Bare, A. Escobar, C. Sarasqueta, N. Fernández de Larrea, J.M. Quintana, E. Pérez-Ruiz, R. Villatoro, D. Perez, M. Redondo
Journal: Annals of Oncology (2017)
Inhibition of p53 function in tumours that express the Pax3 proto-oncogene
Authors: Timothy J. Underwood, Jay Amin, Somayyeh Mossadegh, Karen Lillycrop, Jeremy P. Blaydes
Journal: Cancer Research (2006)

4968  Activation of the tumor suppressor protein p53 leads to cell cycle arrest and/or apoptosis. The p53 protein therefore provides a critical brake on tumor development. The p53 gene is mutated in over half of all human cancers and the p53 pathway is thought to be impaired in the majority of the remainder. Primary tumors derived from the neural crest, including malignant melanoma and neuroblastoma, exhibit a low rate of p53 mutation. Frequently cells derived from these tumors require expression of the embryological oncogene Pax3 for survival. Pax3 is a transcription factor essential for embryological development. Genetic and pharmacological studies in mice have shown that a major role of Pax3 in the developing neural crest is to keep p53 down-regulated until a specific developmental program is completed. We hypothesised that Pax3 expression may lead to p53 functional inhibition in neural crest derived tumors. We have shown that in the malignant melanoma cell line UACC-62, down-regulation of Pax3 using specific siRNA leads to a 91% decrease in cell viability. This is associated with increased PARP cleavage, a marker of apoptosis. This reduction in cell viability in response to Pax3 down-regulation is completely rescued by the addition of p53 specific siRNA. In a model system, Pax3 inhibits the induction of the p53 responsive pro-apoptotic gene Bax by over 50% (p
Phase II study of TAS-116, an oral inhibitor of heat shock protein 90 (HSP90), in metastatic or unresectable gastrointestinal stromal tumor refractory to imatinib, sunitinib and regorafenib
Authors: Y. Kurokawa, T. Doi, A. Sawaki, Y. Komatsu, M. Ozaka, T. Takahashi, Y. Naito, S. Okubo, T. Nishida
Journal: Annals of Oncology (2017)
Twelve-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A1c and Hypoglycemia
Authors: Eyal Dassau, Jordan E. Pinsker, Yogish C. Kudva, Sue A. Brown, Ravi Gondhalekar, Chiara Dalla Man, Steve Patek, Michele Schiavon, Vikash Dadlani, Isuru Dasanayake, Mei Mei Church, Rickey E. Carter, Wendy C. Bevier, Lauren M. Huyett, Jonathan Hughes, Stacey Anderson, Dayu Lv, Elaine Schertz, Emma Emory, Shelly K. McCrady-Spitzer, Tyler Jean, Paige K. Bradley, Ling Hinshaw, Alejandro J. Laguna Sanz, Ananda Basu, Boris Kovatchev, Claudio Cobelli, Francis J. Doyle
Journal: Diabetes Care (2017)

Artificial pancreas (AP) systems are best positioned for optimal treatment of type 1 diabetes (T1D) and are currently being tested in outpatient clinical trials. Our consortium developed and tested a novel adaptive AP in an outpatient, single-arm, uncontrolled multicenter clinical trial lasting 12 weeks.Thirty adults with T1D completed a continuous glucose monitor (CGM)-augmented 1-week sensor-augmented pump (SAP) period. After the AP was started, basal insulin delivery settings used by the AP for initialization were adapted weekly, and carbohydrate ratios were adapted every 4 weeks by an algorithm running on a cloud-based server, with automatic data upload from devices. Adaptations were reviewed by expert study clinicians and patients. The primary end point was change in hemoglobin A1c (HbA1c). Outcomes are reported adhering to consensus recommendations on reporting of AP trials.Twenty-nine patients completed the trial. HbA1c, 7.0 ± 0.8% at the start of AP use, improved to 6.7 ± 0.6% after 12 weeks (-0.3, 95% CI -0.5 to -0.2, P < 0.001). Compared with the SAP run-in, CGM time spent in the hypoglycemic range improved during the day from 5.0 to 1.9% (-3.1, 95% CI -4.1 to -2.1, P < 0.001) and overnight from 4.1 to 1.1% (-3.1, 95% CI -4.2 to -1.9, P < 0.001). Whereas carbohydrate ratios were adapted to a larger extent initially with minimal changes thereafter, basal insulin was adapted throughout. Approximately 10% of adaptation recommendations were manually overridden. There were no protocol-related serious adverse events.Use of our novel adaptive AP yielded significant reductions in HbA1c and hypoglycemia.
Emergency Health Supplies: Present Status of Procurement and Control
Authors: J E MATTHEWS
Journal: JAMA (1963)

Until recently there was no substantial reserve of health supplies in Canada capable of supporting major peacetime or wartime disasters. In 1952, an $18,000,000 stockpile was authorized by the Federal Government of Canada. Purchases were made to a total of $15,500,000 with deliveries to exceed $13,000,000. Over $6,000000 worth of supplies was distributed to eight regional depots across Canada in safe and strategic locations. Plans were made for release and control of supplies to provincial governments for use at all levels of control, and a Resources Planning Unit has been organized. In Canada, undergraduate students in pharmacy receive special civil defence instruction in emergency health supplies service.
When stem cells meet graphene: Opportunities and challenges in regenerative medicine
Authors: None Kenry, Wong Cheng Lee, Kian Ping Loh, Chwee Teck Lim
Journal: Biomaterials (2017)

Recent advances in stem cell research and nanotechnology have significantly influenced the landscape of tissue engineering and regenerative medicine. Precise and reproducible control of the fate of stem cells and their lineage specification have, therefore, become more crucial than ever for the success of stem cell-based technologies. Extensive research has been geared towards developing materials that are capable of mimicking the physiological microenvironment of stem cells and at the same time, controlling their eventual fate. An interesting example of these materials is two-dimensional graphene and its related derivatives. A high specific surface area coupled with superior chemical stability, biocompatibility, and flexibility in functionalization render graphene-based nanomaterials one of the most exciting platforms for tissue engineering and regenerative medicine applications, especially for stem cell growth, proliferation, and differentiation. In this review, we discuss the love-hate relationship between stem cells and graphene-based nanomaterials in tissue engineering and regenerative medicine. We first discuss the role and importance of stem cells in tissue engineering and regenerative medicine. We then highlight the use of nanomaterials for stem cell control, the interaction between stem cells and graphene nanomaterials as well as their biocompatibility, biodistribution, and biodegradability considerations. We also offer our perspectives on the various challenges and opportunities facing the use of graphene and its derivatives for stem cell growth and differentiation.
Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC
Authors: H. Borghaei, C.J. Langer, S. Gadgeel, V.A. Papadimitrakopoulou, A. Patnaik, S.F. Powell, R.D. Gentzler, R.G. Martins, J.P. Stevenson, S.I. Jalal, A. Panwalkar, J.C-H. Yang, M. Gubens, L. Sequist, M.M. Awad, J. Fiore, S. Saraf, H. Raftopoulos, L. Gandhi
Journal: Annals of Oncology (2017)
Políticas nacionais para a prevenção da resistência aos antibióticos – a situação em 17 países Europeus no final do ano 2000
Authors: H Therre
Journal: Eurosurveillance (2001)

Um estudo realizado nos estados membros da Uniao Europeia e na Noruega demonstra que nestes paises, a excepcao de dois, existia em Dezembro de 2000, uma vigilância nacional dos microorganismos resistentes aos antibioticos. Na Italia, Irlanda e Escocia, os sistemas foram estabelecidos muito recentemente (respectivamente em 1998, 1999 e 1999). Alem disso, exceptuando a Irlanda e a Escocia, todos os paises possuem um sistema nacional para a recolha de dados sobre o consumo de antibioticos, nomeadamente, desde 2000 na Austria, Italia e Luxemburgo. Varios destes sistemas foram definidos apos 1998, quando foram publicadas as recomendacoes da conferencia europeia ‘A Ameaca Microbiana’ que decorreu em Copenhaga. Alem disso, desde entao, foram tomadas varias medidas: campanhas de educacao dirigidas a populacao em Inglaterra e Pais de Gales, na Irlanda ou em Franca; a criacao de comites encarregados especificamente da vigilância do consumo em Italia ou da prevencao da resistencia na Belgica ou na Irlanda; publicacoes das recomendacoes sobre a utilizacao correcta dos antibioticos na Austria e Finlândia, etc.
Circulating tumor (ct) DNA captures intrapatient heterogeneity in metastatic colorectal (mCRC) patients (pts) progressing to FOLFIRI+panitumumab
Authors: J. Vidal, J.M. Viéitez, D. Paez, C. Santos, E. Falcó, C. López López, M. Valladares-Ayerbes, L. Robles, P. Garcia-Alfonso, G. Duran Ogaya, D. Azuara, A. Dalmeses, B. Bellosillo Paricio, G. CAPELLA, R. Salazar, E. Aranda Aguilar, C. Montagut
Journal: Annals of Oncology (2017)